TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07422311: A Phase 2/3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease

Sponsor: Benuvia Therapeutics Inc. · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,147,520

Rescue Site Savings

+$9,987,896

Unlock Full NCT07422311 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07422311 Rescue Dossier →